$40.28 -1.53 (-3.66%) Alnylam Pharmaceuticals Inc - NASDAQ

Dec. 7, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 40.28
Trade Time: Dec 07 04:00 PM Eastern Daylight Time
Change: -1.53 (-3.66%)
Prev Close: 41.81
Open: 40.77
Bid: 40.28
Ask: 40.29
  1. Market Reversal In Biotech But Healthcare Stocks Are Still Muddled

    TalkMarkets | Nov. 29, 2016 | 22:56PM EST
  2. Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved

    TalkMarkets | Nov. 16, 2016 | 15:30PM EST
  3. Rayno Biobeat #3…Trump Biotech Rally Leads Market Up

    TalkMarkets | Nov. 9, 2016 | 23:23PM EST
  4. IPO Preview: Ra Pharmaceuticals

    TalkMarkets | Oct. 26, 2016 | 01:02AM EST
  5. Biotechnology Bear Market: Trends To Watch For A 2016 Q4 Rally

    TalkMarkets | Oct. 12, 2016 | 23:02PM EST
  6. Biotech Stock Roundup: Alnylam Slumps On Revusiran Update, TESARO Impresses At ESMO

    TalkMarkets | Oct. 12, 2016 | 11:14AM EST
  7. Battleground: Alnylam Plunges After Revusiran Pulled, But Some See Opportunity

    TalkMarkets | Oct. 6, 2016 | 19:50PM EST
  8. Morning Call For October 6, 2016

    TalkMarkets | Oct. 6, 2016 | 08:17AM EST
  9. Biotech Stocks Recovering From Last Week’s Free Fall

    TalkMarkets | Oct. 5, 2016 | 23:06PM EST
  10. Medicines Co. up on sale talk

    IBD | Jan. 20, 2016 | 18:40PM EST
  11. Medicines Company Spikes On Report Of Possible Sale

    IBD | Jan. 20, 2016 | 12:59PM EST
  12. Alnylam Pharmaceuticals Dips Lower After Company Announces 2016 Pipeline Goals Towards 'Alnylam 2020'

    Benzinga | Jan. 11, 2016 | 13:57PM EST
  13. Alnylam Reports Positive Phase 1 Study Results for Once-Monthly, Subcutaneous Fitusiran (ALN-AT3) in Patients with Hemophilia A and B

    Benzinga | Dec. 7, 2015 | 10:30AM EST
  14. Breakaway Gaps By Stocks Can Be Scary But Profitable

    IBD | Dec. 3, 2015 | 17:58PM EST
  15. Leerink Highlights Biotechs Poised To Benefit From ASH Conference

    Benzinga | Nov. 30, 2015 | 13:13PM EST
Trading Center